Intuitive Surgical announces U.S. FDA cleared software advancements

Intuitive announced that the U.S. Food & Drug Administration has cleared software advancements for the Ion endoluminal system. Ion, Intuitive’s robotic-assisted bronchoscopy platform, features an ultra-thin, shape-sensing catheter designed to navigate deep into the lung. This advanced technology enables physicians to access small, hard-to-reach nodules and precisely position biopsy tools to sample potentially cancerous tissue. “These latest Ion software advancements reflect Intuitive’s ongoing commitment to advancing lung cancer care through meaningful innovation,” said Intuitive Chief Executive Officer Dave Rosa. “By further integrating artificial intelligence with expanded advanced imaging capabilities, we’re equipping physicians with smarter tools designed to support early diagnosis and improve access to advanced care for more patients.”